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Adult murine hosts injected with Moloney sarcoma virus  (MSV)  1 develop 
tumors at the site of inoculation which undergo spontaneous regression in a 
high percentage of the animals (1). In vivo studies implicate thymus-dependent 
cell-mediated immune mechanisms (2) as well as humoral immunity (3) in the 
regression event. In vitro, specific antibodies (4-7) and lymphocytes (4, 8, 9-15) 
from animals undergoing induction and regression of MSV tumors, have activ- 
ity against tumor target cells bearing the appropriate virally determined anti- 
gen(s). Such animals develop humoral antibodies of both the M and G classes 
which have specificity for the virally determined cell surface antigen(s) (5). IgM 
as well as IgG, with specificity for the tumor target cells, can induce cytotoxicity 
by normal lymphocytes and potentiate the cytotoxicity of immune lymphocytes 
(16). Investigations into the subpopulations of cells involved as cytotoxic effector 
cells against IgM-coated target cells led to the findings that splenic T and B cells 
from normal or MSV regressor animals were induced to be cytotoxic or poten- 
tiated in their cytotoxicity by immune IgM; nonphagocytic cells of the spleen 
possessing neither surface Ig nor thymus-specific antigens were found not to be 
active against IgM-coated target cells (17). Furthermore, normal thymocytes 
were highly cytotoxic against the IgM-coated target cells (17, 18). 
The purpose of the present investigation was to evaluate the differential 
activity  of IgG  and IgM from MSV regressor animals in  combination with 
lymphocytes from spleen, lymph node, and thymus, and to determine whether 
the antibody-dependent thymocyte-mediated cytotoxicity could be ascribed to a 
particular subset of thymocytes. 
* This work was performed persuant to Contract NO1-CP-43394 from the Virus Cancer Program 
and grant CA A1  17273-01,  National Cancer Institute, National Institutes of Health.  Credit is 
given to project number 5132-01 from the Veterans Administration Hospital, Birmingham, Ala. 
Recipient of a  Research Career Development Award from the National Cancer Institute. 
§ Recipients of predoctoral training grant from the Department of Microbiology, University of 
Alabama in Birmingham. 
' Abbreviations  used  in this paper:  FCS,  fetal calf serum;  MEM,  Eagle's minimal essential 
medium; MLV, Moloney leukemia virus; MSV, Moloney sarcoma virus. 
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Materials and Methods 
Animals.  Young adult BALB/c and CBA mice of both sexes,  6-12 wk of age,  were used as 
sources of sera and lymphocytes. 
Virus.  MSV-B-64 was obtained from the Office of Progress Resources  and Logistics,  Viral 
Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Md. This prepara- 
tion has a  titer of 6.2  log/FFU  per ml on 3T3  cells.  0.1  ml  of this preparation,  when injected 
subcutaneously into adult mice, regularly produced tumors within 10-15 days after injection. 
Inoculations.  BALB/c mice were injected with 0.1 mt of the MSV suspension intramuscularly 
into the thigh. Local tumors developed as early as 5 days reaching a peak tumor size of 10-15 mm 
in diameter on day 15 and usually completely regressing by days 20-25. Regressor animals were 
bled at 30 days after the injection of virus, and the sera were pooled and heat inactivated at 56°C 
for 30 min.  The data reported in this manuscript represent two serum pools collected from  10 
animals each. 
Antibody Fractionation.  Serum was fractionated on Sephadex G-200 as previously described 
with a  90 x 2.5-cm column (16, 17, 19). The leading half of the first protein peak and the trailing 
half of the second peak were collected separately and reconcentrated to the original serum volume. 
With one of the serum pools (pool no.  1) the leading half of the 19S peak was refractionated on 
Sephadex G-200 and the leading half of this peak collected and reconcentrated. After reconcentra- 
tion, IgM and IgG fractions were found to be free of cross-contamination by immunodiffusion and 
immunoelectrophoresis. 
Medium.  Eagle's  minimal  essential  medium  (MEM)  with  10%  heat-inactivated fetal  calf 
serum (FCS) and 100 ~g/ml of gentamycin was used. 
Lymphoid Cells.  Spleens, lymph nodes, and thymi from young adult CBA mice were dissected 
out under sterile conditions and prepared separately as follows. The organs were passed through 
fine nylon mesh into cold MEM without FCS, mixed with a Pasteur pipette, and passed over a fine 
nylon mesh filter. The cells were pelleted by centrifugation, and spleen cells were resuspended in 
Tris (hydroxymethyl-aminomethane)-buffered, 0.75% ammonium chloride, pH 7.2, and incubated 
for 10 min at 37°C to lyse the erythrocytes. This step was omitted with thymus and lymph node 
cells  when  erythrocyte  contamination was  minimal.  The  cells  were  washed  once  with  MEM 
without FCS and resuspended in complete medium. 2-4  x  108 cells prepared as above in 5 ml of 
MEM were mixed with iron powder and incubated for 30 min at 37°C with agitation every 5-10 
min. Iron and phagocytic cells were removed by passing the suspension through a  series of five 
sterile tubes using a magnet to retain the iron in the discarded tube. The cells were then washed 
twice with MEM before use. The cells were counted in a hemacytometer, and appropriate dilutions 
were used in microcytotoxicity assays. 
Thymocyte Fractionation.  The approach taken in this series of experiments was to pharmaco- 
logically fractionate the thymocytes in vivo by injecting cortisone acetate. 6- to 8-wk-old CBA mice 
were injected with 2.5 mg of cortisone acetate. The thymi were harvested from such animals at 2 
days after injection of cortisone when the thymus is reduced to approximately 5% of its original cell 
number and  the  remaining cortisone  resistant  cells  have  been  shown to  be  immunologically 
competent (20).  Also, thymi were harvested at 12 days after cortisone injection when the thymus 
has become repopulated to near normal size, and the cells have a  lower immunologic reactivity 
than normal thymocytes (21).  Processing of the lymphocytes was as described above. Thymocytes 
prepared in this way from control animals or after cortisone injection contain less than 1% B cells 
by direct anti-Ig immunofluoresence. 
Target Cells.  Ha2  is a  cell culture line established from an MSV-induced tumor of a  CBA 
mouse. These cells produce infectious virus, possess Moloney leukemia virus (MLV)-determined 
cell surface antigen(s), (4, 22) and have been shown to be sensitive to MSV immune lymphocytes in 
microcytotoxicity assays (4, 9-12), but not to lymphocyte immune to a nonpertinent antigen (9, 10, 
23). These cells have also been shown to be sensitive to antibody-dependent cell-mediated cytotox- 
icity by using antibody with specificity for MLV-determined antigens and normal or MSV immune 
lymphocytes (16-18). 
D-56 cells are sarcoma positive, leukemia negative cells derived from 3T3 NIH Swiss embryo 
fibroblast cultures. The cells possess the sarcoma genome, but do not produce any infectious virus 
nor do  they  possess  any  virally associated  surface  antigen that would  distinguish them  from 
normal 3T3 cells utilizing murine antisera (4).  They are not sensitive to MSV immune lympho- 304  IgM-  AND  IgG-DEPENDENT  CELL-MEDIATED  CYTOTOXICITY 
cytes  (4,  9-11).  However,  the  same  cells  superinfected  with  MLV  and  thus possessing  MLV- 
determined  antigen(s)  are  sensitive to  MSV  immune  lymphocytes  (4,  11).  This  cell  line  was 
provided through the courtesy of Dr. R. H. Bassin, National Institutes of Health, Bethesda, Md. 
Py3T3  cells are polyoma virus-transformed BALB/c 3T3  cells,  kindly provided by Dr.  Gene 
Majors,  Department of Microbiology, University of Chicago, Ill. These cells do not possess any 
MLV-determined cell surface antigens, but are sensitive to immune lymphocytes from animals 
that have been immunized against polyoma-transformed tumor  cells  (A.  S.  Walia and E.  W. 
Lamon, unpublished observation). 
Microcytotoxicity  Assays.  A modification of the microcytotoxicity assay of Takasugi and Klein 
(24) was used to determine antibody-dependent cell-mediated cytotoxicity (16-18). Briefly, 200 Ha2 
cells in 5 ~1 vol of complete medium were seeded into each of the wells of microplates (3034 Falcon 
Plastics, Div. of BioQuest, Oxnard, Calif.). Plates were incubated at 37°C in 5% CO2 for 3-4 h  to 
allow attachment of target cells. Serial dilutions of the antisera or their Sephadex G-200 fractions 
were then added to the wells,  six replicates per dilution in vol of 5  pl per well.  The sera were 
allowed to  incubate with the target cells for  1 h,  after which  10,000  lymphoid cells  (or serial 
dilutions as indicated in the Results section) were added to each of the wells. After incubation at 
37°C  in 5%  CO2 for 20-24  h,  the medium was removed and the plates were washed once with 
balanced salt solution to remove dead cells. The plates were fixed and stained, and the target cells 
remaining in each well or a representative portion thereof were counted. (Hereafter, a reference to 
well indicates the number of target cells remaining in the well.) 
Evaluation of Results 
DETERMINATION OF PERCENT TARGET CELL REDUCTION BY  LYMPHOID CELLS FROM SPLEEN,  LYMPH 
NODE, AND THYMUS.  The loglo mean and standard deviation (SD) of the six replicate wells were 
determined,  and a  Student's t  test was performed to assess the significance of the differences 
between test wells containing antibody and lymphocytes and the control wells containing only 
lymphocytes. A significant difference was considered to exist at P  values ~ 0.05. Percent reduction 
of the target cells in wells  containing immune antibody and lymphocytes  was  calculated and 
compared with wells containing lymphocytes only by using the geometric mean of the six replicate 
wells for each serum dilution according to the following formula: 
Geometric mean of test wells 
% reduction =  100 -  ×  100 
Geometric mean of control wells 
The endpoint titer of an antiserum was considered to be the last dilution producing significant (P 
-~ 0.05) target cell reduction compared to the control. As a further control, the antiserum and its 
fractions were tested on control cells in combination with the same number and kind of lympho- 
cytes as used on the Ha2 target cells. 
CALCULATION OF A% REDUCTION.  To compare the activity of thymocytes from the two experi- 
mental groups  of cortisone-treated animals,  the change in percent reduction at each antibody 
dilution was calculated according to the following formula: 
A% reduction =  100 
% surviving target cells with thymocytes from cortisone-treated animals 
-  x  100 
% surviving target cells with control thymocytes 
To combine the data from more than one experiment, each sample containing thymocytes from 
cortisone-treated animals was  converted to  a  A%  reduction  value utilizing the  mean  percent 
surviving target cells with control thymocytes and the same dilution of antibody for the denomina- 
tor of the above formula. The arithmetic mean  -  standard error of the A% reduction was then 
calculated for each point of each experimental group with combined experiments. P  values were 
determined using  a  Student's t  test to  compare  the  percent  surviving target  cells  from  each 
experimental group with the percent surviving target cells with control thymocytes tested with 
the same fraction and dilution of antibody. The number of samples for each point in the experi- 
mental groups was  12-18,  and the number of samples in the controls was 24-30.  Thus, the A% 
reduction indicates an increase or decrease in the ability of thymocytes from cortisone-treated 
animals to be cytotoxic against the target cells in vitro, as compared to thymocytes from control 
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the A% reduction calculated is antibody dependent. The number of surviving target cells  incu- 
bated with thymocytes  alone without  antibody  exhibited no significant differences between 
groups. From a single experiment the loglo  mean number of  target cells  remaining in wells with 
thymocytes only was 2.36 _+  0.10,  2.36 --+-  0.26,  and 2.35 _+  0.13 with control thymocytes, thymocytes 
2 days after  cortisone injection,  and thymocytes 12  days after  cortisone treatment, respectively. 
Results 
Both the IgM and IgG fractions of MSV regressor serum pool no. 1 were able 
to induce specific cytotoxicity by lymph node cells as indicated in Fig.  1. The 
end point titer for IgM against Ha2 cells was 1:80, and the end point titer for 
IgG against the Ha2 target cells was 1:40. This cytotoxicity  was specific for the 
Ha2 target cells. No cytotoxicity was produced against Py3T3 cells with the 
same combinations of antibody and lymphocytes. Similarly no cytotoxicity  was 
produced against D-56 cells with the same antibody and lymphocytes (data not 
shown). In addition to this specificity control shown in the figure, the antise- 
rum or its Sephadex fractions produced no cytotoxicity against the Ha2 cells 
without the addition of lymphocytes or complement. Using similar controls, 
the antibody-dependent  specificity was also confirmed  with spleen and thymus 
effector cells. 
Fig.  2 shows the ability of IgM and IgG from the same pool  of serum to 
induce cytotoxicity by normal spleen cells against the Ha2 target cells. The 
end point titer for IgM was 1:160, and the end point titer for IgG was 1:20. 
In contrast, thymocytes from control animals were exclusively cytotoxic in 
combination with IgM. No significant control thymocyte-mediated  cytotoxicity 
was induced by IgG from this pool of regressor serum as indicated in Fig. 3. 
The end point titer of IgM in combination with thymocytes was 1:80. 
To determine the relative efficiency of lymphoid cells from the different 
organs as effector cells against the antibody-coated target cells, the antibody 
fractions were placed on the target cells at a  constant concentration (1:20) 
followed by  graded numbers of lymphocytes from  spleen,  lymph node,  or 
normal thymus. As indicated in Table I, when IgM was used as the sensitizing 
antibody, as few as 2,500 lymph node cells produced a  significant target cell 
reduction. Thymus required 5,000 cells and spleen 10,000 to produce a signifi- 
cant target cell reduction against the IgM-coated targets. When IgG was used 
as  the  sensitizing antibody, both  spleen and  lymph node cells were about 
equally efficient as  effector cells.  Thymus cells,  however, were not  active 
against the IgG-coated tumor target cells. 
The following experiments with thymocytes from cortisone-treated animals 
were performed with dilutions of antibody and a  constant concentration of 
lymphocytes (10,000/well).  The preceeding experiments were performed with 
serum pool no. 1, the following with serum pool no. 2. 
Fig.  4 shows the differential activity of thymocytes from cortisone-treated 
animals compared to control thymocytes in  the presence of unfractionated 
MSV regressor antiserum. As indicated, the cortisone resistant thymocytes at 
2 days after cortisone injection exhibited a very strong increase in cytotoxicity 
against Ha2 cells, whereas with the 12-day repopulated thymus, no significant 
change  was  evident.  Also,  against  Ha2  target  cells  coated with  the  IgM 
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Fro.  1.  IgM- and IgG-dependent cell-mediated cytotoxicity with lymph node effector cells; 
specificity of the reaction. The IgM and IgG were prepared from pool no. 1 MSV regressor 
sera described in the text.  The solid horizontal line at 0 represents the activity of lymph 
node cells alone. The percent reduction at each antibody dilution was calculated according 
to the formula in the text.  Points at or below the solid horizontal line indicate a  lack of 
target cell reduction or stimulation of target cell growth,  respectively.  A  second control 
target cell used in these experiments, D-56 cells, revealed essentially the same pattern as 
Py3T3 cells. The end point titer for IgM against Ha2 cells was 1:80.  The end point titer for 
IgG against Ha2 cells was 1:40. 
produced a very strong increase in cytotoxicity, and there was a slight decrease 
in the cytotoxicity  observed with the 12-day repopulated thymocytes (Fig. 5). 
As indicated in Fig. 6, the 2-day cortisone resistant thymocytes were cyto- 
toxic also  against IgG-coated Ha2  target cells.  This was not observed with 
control thymocytes (see Fig. 3 and Table I). Cells from the 12-day repopulated 
thymus exhibited little change from control thymocytes in combination with 
IgG,  one  antibody dilution  producing a  significant increase in  target cell 
reduction and another antibody dilution producing a  significant decrease in 
target cell reduction. (The latter represents a stimulation in target cell growth 
since IgG was not found to induce cytotoxicity with control thymocytes). 
Discussion 
We have thus presented an analysis of the effector cells involved in anti- 
body-dependent cell-mediated cytotoxicity against tumor cells sensitized with 
IgG or IgM antibody from MSV regressor mice. With serial antibody dilutions 
and a constant concentration of effector cells (10,000/well), lymph node, spleen, 
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Fro.  2.  IgM-  and IgG-dependent cell-mediated cytotoxicity with spleen cells as effector 
cells against Ha2 target cells. The percent reduction at each antibody dilution was calcu- 
lated as in Fig. 1. The IgM and IgG were the same as those represented in Fig. 1. The end 
point titer for IgM was 1:160.  The end point titer for [gG was 1:20. 
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FIG.  3.  IgM- and IgG-dependent cell-mediated cytotoxicity against Ha2 cells with thymo- 
cytes as effector cells. The percent reduction was calculated as in Fig. 1. The IgM and IgG 
fractions are  the  same  as those  illustrated in Figs.  1  and 2.  The IgG did not induce a 
significant cytotexicity at any dilution. The end point titer for IgM was 1:80. 
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TABLE  I 
Lowest Concentrations of Lymphocytes Producing Significant Target Cell Reduction  at 
Constant Antibody Dilutions 
MSV-R antibody fraction 
Source of lympho-  IgM  IgG 
cytes* 
Dil.~  % red.§  /~l  Dil.  % red.  P 
Spleen  104  17%  <0.05  104  20%  <0.005 
Lymph node  2.5  ×  103  27%  <0.005  104  15%  <0.0005 
Thymus  5  ×  102  22%  <0.005  None  NS  NS¶ 
Target cells used were Ha2 cells. The mean number of cells in control wells was 160 _  19.5. 
* Phagocyte-depleted lymphoid cells from control CBA animals tested at concentrations 2  ×  104, 
1.5 x  104, 104 , 5  ×  103 , and 2.5  ×  103 per well. 
Dilution: lowest number of lymphocytes per well giving significant target cell reduction in the 
presence of antibody. 
§ % red.: percent reduction calculated by the formula in the text produced by the lowest dilution 
of lymphocytes giving significant (P <  0.05) reduction. 
II P  values obtained using a  Student's t  test compared to wells containing the same number of 
lymphocytes without antibody. 
¶ NS, not significant. 
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Fro.  4.  Change in antibody-dependent thymocyte-mediated cytotexicity against Ha2 cells 
after  cortisone  injection.  The  antibody  used  was  unfractionated  antiserum  from  MSV 
regressor  pool  no.  2.  The  solid  horizontal  line  at  0  represents  the  activity  of  control 
thymocytes with the same antibody dilutions tested in an identical manner. A% reduction 
was calculated according to the formula in the text and represents an increase or decrease of 
cytotoxicity compared  to  control thymocytes tested with  identical  antiserum  concentra- 
tions. P  values were derived using a  Student's t test to compare each experimental group 
with the  control thymocytes at  each antibody dilution.  The  vertical bars represent the 
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Fro.  5.  The change in IgM antibody-dependent thymocyte-mediated cytotoxicity against 
Ha2 cells after cortisone injection. The IgM was obtained from MSV regressor serum pool 
no. 2. The calculations were performed as in Fig. 4. 
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Fro.  6.  The change in IgG antibody-dependent thymocyte-mediated cytotoxicity against 
Ha2 cells following cortisone injection. The IgG was obtained from MSV regressor serum 
pool no. 2. Calculations were performed as in Fig. 4. 
cytes were more cytotoxic against IgM-sensitized target cells than spleen and 
lymph node cells. Against IgG-coated target cells, lymphocytes from spleen 
and lymph node were cytotoxic but thymocytes were not. IgM induced a higher 
maximum cytotoxicity and end point titer than IgG with lymphocytes from all 
three organs. Using a constant antibody concentration, the number of lympho- 
cytes required to produce cytotoxicity was evaluated. Lymph node cells and 
thymocytes were more efficient effector cells against IgM-coated target cells 
than spleen cells. Against IgG-coated target cells, spleen and lymph node cells 
were  about  equally  efficient,  and there  was  no observed cytotoxicity with 
normal thymocytes. 
Utilizing cortisone as a means of in vivo fractionation, the major cytotoxicity 
observed with  IgM  and  control thymocytes could be  accounted for by  the 
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were not induced to by cytotoxic by IgG,  a  significant cytotoxicity was pro- 
duced against  IgG-coated tumor cells when cortisone resistant  thymocytes 
were used as the effector cells. 
Previous work with splenic effector cells indicated that phagocytic cells do 
not contribute to this antibody-dependent cell-mediated cytotoxicity using the 
same target cells and the same assay system (16). Furthermore, cells possess- 
ing high concentrations of surface immunoglobulin (B cells), as well as cells 
possessing thymus-specific antigens (T cells), were found to be active against 
IgM-treated target cells. However, nonphagocytic spleen cells depleted of both 
B and T cells were not active (16). Since the thymocytes used in the present 
experiments contain less than 1% B  cells and the suspensions were treated 
with iron powder and magnetism, it seems unlikely that the antibody-depend- 
ent cell-mediated cytotoxicity effector cells from the thymus are contaminat- 
ing B cells or macrophages. 
Antibody-dependent cell-mediated cytotoxicity has been described in a num- 
ber  of systems  (25-29),  including the  MSV  system  (12,  16-18,  30-32).  The 
antibody class responsible for this activity had been ascribed to IgG in some of 
these systems, and IgM was not found to be active. However, in two murine 
systems, both IgG and IgM have been found to induce cell-mediated cytotoxic- 
ity. We found that both IgG and IgM antibody from MSV regressor animals 
induced cytotoxicity by normal lymphocytes and potentiated the activity of 
immune lymphocytes against  target  cells  bearing  the  appropriate  virally 
determined surface antigen(s)  (16). Also,  Dennert and Lennox (33) reported 
that both IgM and IgG from mice immune to chicken erythrocytes (CRBC) 
induced CRBC lysis by lymphoid cells.  More recently, Blair et al.  (34) have 
reported arming activity exclusively in the IgM fraction in the mouse mam- 
mary tumor virus system. 
One of the major concerns in the present series of experiments is the purity 
of the 19S antibody fraction. In previous reports, the 19S antibody from MSV 
regressor mice was shown to be IgM by size and by immunologic specificity 
(16). In  the  present  report,  the  differential  activities  of the  two  antibody 
fractions in terms of their ability to induce cytotoxicity by lymphocytes from 
different organs provide additional evidence that the activities described are 
indeed due to IgM and IgG antibodies, respectively. 
A number of previous studies (27, 28), including investigations reported by 
ourselves (6), had indicated that T cells were not required for antibody-depend- 
ent cell-mediated cytotoxicity. However, we have found that thymocytes and 
peripheral T cells can be involved in antibody-dependent cell-mediated cytotox- 
icity, particularly when IgM is used as the sensitizing antibody (17, 18). Fur- 
thermore, the present series of experiments demonstrate that cortisone resistant 
thymocytes can be active against both IgM- and IgG-coated target cells. 
The interaction of immune antibody and lymphocytes at the effector level may 
play a  key role in the regression of MSV-induced tumors. Both humoral anti- 
body and thymus-dependent cell-mediated immunity have been shown to be 
important in vivo for tumor resistance in this system. Antibody from regressor 
animals  has  been  shown to  protect previously  unimmunized hosts  against 
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demonstrated that the thymus is required for spontaneous regression of  primary 
MSV  tumors  (2). The  data  described  in  the  present  report  would  seem to 
reconcile both the above groups of data (humoral and cellular) at the effecter 
level.  The thymus may be  needed for the  animals to  produce an  adequate 
antibody response against the virally determined antigen(s), and/or the thymus 
may provide cytotoxic effector cells.  The latter could involve direct tumor cell 
cytotoxicity by immune lymphocytes or, as demonstrated in the present report, 
antibody-induced thymocyte-mediated  cytotoxicity by a  specific subpopulation 
of thymocytes. The  structural  bases  for  antibody-dependent thymocyte-me- 
diated cytotoxicity would appear to be Fc receptors on T  cells. This includes 
receptors for the Fc portion of IgG (35) and more recently demonstrated recep- 
ters for IgM Fc (36, 37). In addition to the implications in this particular tumor 
model, these data provide evidence that antibody secreted by B cells can direct 
functional events mediated by T cells, in this case cytotoxicity. 
Summary 
Antibody-dependent  cell-mediated cytotoxicity in the Moloney sarcoma virus 
(MSV) system was evaluated in terms of the differential ability of IgG and IgM 
from MSV regressor animals to induce cytotoxicity by lymphocytes  from lymph 
node, spleen, and thymus. The cell-mediated cytotoxicity induced by both IgM 
and IgG was specific for target cells possessing the appropriate virally deter- 
mined cell surface antigen(s). IgM induced cytotoxicity  by lymphocytes  from all 
the organs tested. However, differences in magnitude and efficiency were re- 
vealed.  Lymph node cells and thymocytes were most efficient against IgM- 
coated target cells. Against IgG-sensitized target cells, spleen and lymph node 
cells were about equally active, but thymocytes were inactive. Cortisone treat- 
ment of the donors of effector cells revealed that the cortisone resistant subpopu- 
lation of thymocytes, 2 days after cortisone injection, exhibited an increased 
cytotoxicity against target cells treated with unfractionated antiserum and its 
IgM fraction. This subpopulation of thymocytes  was also cytotoxic against IgG- 
coated target cells. At 12 days ai~r cortisone injection, the repopulated thymus 
showed little .change in activity, compared to control thymus, against antibody- 
coated target cells. 
Received for publication 20 October 1976. 
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